An ongoing research at Mount Sinai being conducted by Icahn School of Medicine led to the discovery of a drug which may become a replacement to pain-killing medications which has an addictive risk such as morphine and opioids. CYM51010, a compound that may have therapeutic actions as analgesics like morphine, was discovered by Mount Sinai’s Pharmacology and Systems Therapeutics Professor, Dr. Lakshmi Devi and her team in a previous study.
The said compound acts on the GPRC heteromer, a protein complex that has delta and mu opioid receptors. These receptors are also found rich in the brain areas where pain sensation is being commanded or stopped. It is the same area where the tolerance for morphine and any undesirable effects are most likely being processed.
The researchers of the National Institute of Health, Dr. Marta Filizola, Mount Sinai’s Structural and Chemical Biology Professor, and Dr. Devi and her team of researchers have joint forces and are now working on a follow-up research. They are trying in a screening to name which molecules may be acting on the pathway that signals the said protein complex.
The team is aiming on developing CYM51010 minus any possibilities of developing dependency during its treatment use. In addition to that, they are planning to limit the drug’s action on the gastrointestinal system and address irritable bowel syndrome’s accompanying diarrhea which is not responding to present available medications.